Huntington’s Disease Treatment Market Size, Share, By Drug, Therapy Type, Route of Administration, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2035

• Huntington’s disease treatment market size is expected to grow at USD 3.5 billion by 2035.
• The target market was valued at USD 1.28 billion in 2024.
• Target market is expanding at a CAGR of 11.8%.

Huntington’s disease (HD) is a rare hereditary neurodegenerative disorder characterized by chorea, cognitive decline, and psychiatric disturbances. It is a genetic condition that affects the cells in brain and it’s a progressive condition that gets worse over time. Target market is driven by high burden of HD in western countries and strong product pipeline of disease-modifying therapies. In addition, increasing population and rise in demand for advanced drug types for controlling the symptoms are another factors propelling growth of the global market. Furthermore, technological advancements, which increases the efficiency and cost-effectiveness of production is also anticipated to create opportunities for growth of the global market over the forecast period.

Key Takeaways:

• North America held the largest share of the market in 2024 due to rising awareness regarding this disease.
• Asia Pacific is projected to be the fastest-growing market in the coming years. This is due to increase in patient population.

Key Drivers of Target Market:

Rising Cases of Huntington’s Diseases is Expected to Propel Market Growth

There is no cure for HD. However, many therapeutic options exist for treating signs and symptoms with the aim of improving the quality of life. As diagnostic techniques and awareness improve, more individuals are being diagnosed with Huntington's disease, leading to greater demand for treatments.

• For instance, according to the data published by Cleveland Clinic, Huntington’s disease affects an estimated 3 to 7 out of every 100,000 people, most often to people of European ancestry (biological family comes from European descent).
• For instance, according to the data published by National Library of Medicine in June 2023, the prevalence in the Caucasian population is estimated to be four to ten cases per 100,000 people. Most cases of HD manifest in adulthood between the third and fifth decade of life.

Rising Government Initiatives to Spread Awareness Regarding Huntington’s Disease to Drive Market Expansion

Governments around the world are executing many programs, trainings, workshops, and campaigns to spread awareness regarding Huntington’s disease. This leads to more people getting diagnosed and a greater demand for advanced treatments. A better understanding of Huntington's disease is leading to earlier diagnosis allowing patients to start treatment sooner and improve their quality of life.

• For instance, in May 2024, the Huntington’s disease Society of America (HDSA) celebrated 32 years of Huntington’s disease Awareness Month with a series of events across the country and an online initiative called #letstalkabouthd. This campaign seeks to raise awareness and support for those affected by Huntington’s disease (HD), culminating in the HDSA Annual Convention, the largest gathering of HD families in the world, to be held in Spokane, WA.

Restrains:

Side Effects of Medications May Hamper the Growth of the Market

Medications used to treat Huntington's disease (HD) can have side effects, such as fatigue, sedation, decreased concentration, restlessness, hyper excitability, nausea, vomiting, and diarrhea, among others. These medications do not affect the progression of the disease. However, they can increase the risk of worsening or triggering depression or other psychiatric conditions. 

• Counterbalance Statements: Solutions over this problem are staying active, working with a physiotherapist to improve movement, eating healthy food, staying hydrates, and among others.

Opportunities:

Increasing Research Activities Will Create Significant Opportunities in Upcoming Years

Each patient of Huntington’s disease has a unique combination of symptoms, and although these can be managed using a range of medications and non-drug treatments there is currently no cure for the disease. Thus, many researchers are focusing on new development of therapy to treat this disease.

• For instance, in September 2024, a study from researchers in Berlin & Dusseldorf has identified a novel gene, CHCHD2, which could play a crucial role in the progression of HG. This discovery offers new insights into the mechanism of the disease and potential avenues for therapeutic intervention.
• For instance, in August 2024, new data from uniQure, who developed a one-and-done gene therapy for Huntington’s disease (HD) called AMT-130, indicates that the drug is relatively safe and might be able to slow down signs and symptoms of HD. AMT-130 is currently under investigation in Phase I/II clinical trials in Europe and the US which are mainly focused on drug safety. 

The market is segmented based on drug, treatment, diagnosis type, route of administration, distribution channel, and region. 

Drug

On the basis of drug, the Huntington’s disease treatment market is segmented into tetrabenazine, deutetrabenazine, valbenazine, and others. The tetrabenazine segment dominate the target market growth with 48% of total share as they are most cost-effective, have higher demand, and others.

• For instance, according to the data published by Huntington’s disease News in May 2024, Xenazine (tetrabenazine) is an oral therapy approved to ease chorea, the irregular and uncontrolled movements that affect most people with Huntington’s disease. Xenazine is sold in the U.S. by Lundbeck Pharmaceuticals. It is marketed by other companies under the brand name Nitoman in Canada and certain European countries, including Germany. Generic versions are available as well. The therapy is also approved for other movement disorders, including tardive dyskinesia, in certain countries such as the U.K., but not the U.S.

Therapy Type

The Huntington’s disease treatment market by therapy type is segmented into symptomatic treatment, disease-modifying therapies, and others. The symptomatic treatment holds the largest share of the market due to its growing demand and its widespread applications.

• For instance, according to the article published by Huntington’s disease News, an inability to correctly identify face-like objects and fewer brain signals associated with facial recognition were found in people with Huntington’s disease who had yet to show symptoms, suggesting these tests can be a marker of early disease progression.

Route of Administration

The Huntington’s disease treatment market by route of administration is segmented into oral, parenteral, and others. The oral route segment is expected to dominate the target market growth due to increasing acceptance and demand.

• For instance, in December 2024, PTC Therapeutics Inc. has signed an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG, for its PTC518 Huntington’s disease program, which includes related molecules. Under the deal, Novartis will in-license PTC518, an mRNA splice modulator for the Huntington gene, which has the potential to be the first oral disease-modifying therapy for Huntington's disease.

Distribution Channel

Based on distribution channel, the Huntington’s disease treatment market is segmented into hospital pharmacies, drug stores & retail pharmacies, online pharmacies, and others. The hospital pharmacies holds the largest Huntington’s disease treatment market share as they are well-equipped to provide specialized medications.

Regional

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America is expected to dominate the growth of the market during the forecast period due to the rising disease awareness, increasing collaboration & support between public & private organization for advance research, robust hospital infrastructure, advance technologies, and others.

• For instance, in July 2024, new research led by UCLA Health revealed that About 41,000 Americans have the disease and 200,000 are at risk of inheriting it. 

Asia Pacific: Asia Pacific region is considered to be the fastest growing region in the target market as countries such as India, China and many more are leading the charge significantly due to increase in patient population, healthcare infrastructure & investment projects, and among others. 

• For instance, in November 2024, Alnylam Pharmaceuticals has launched a Phase 1 clinical trial to test the safety and pharmacological properties of its treatment candidate ALN-HTT02 in adults with Huntington’s disease. The Phase 1 trial (NCT06585449) is expected to enroll up to 54 adults, aged between 25-70, with stage 2 or early stage 3 Huntington’s. 

Huntington’s Disease Treatment Market Report Scope:

Segmentation:

By Drug:

• Tetrabenazine
• Deutetrabenazine
• Valbenazine
• Others

By Therapy Type:

• Symptomatic Treatment
• Disease-Modifying Therapies
• Others

By Route of Administration:

• Oral
• Parenteral
• Others

By Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Other

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the Huntington’s disease treatment market include Sun Pharmaceutical Industries Ltd., H. LUNDBECK A/S, Bausch Health Companies Inc., Hikma Pharmaceuticals PLC, and Alnylam Pharmaceuticals, Inc., among others. These key players are focusing on different organic and inorganic strategies, such as acquisition, merger, partnership, agreement, product launch, and approval to expand their product portfolio and strengthen their market presence globally.

List of Key Players in the Market:

• Sun Pharmaceutical Industries Ltd.
• H. LUNDBECK A/S
• Bausch Health Companies Inc.
• Hikma Pharmaceuticals PLC
• Alnylam Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Ionis Pharmaceuticals
• LUPIN
• Neurocrine Biosciences, Inc.
• Prilenia Therapeutics B.V.
• Azevan Pharmaceuticals
• SOM BIOTECH
• UniQure NV
• ANNEXON, INC

• In December 2024, in a recent study published in JAMA Neurology, researchers investigated whether β-blockers, which regulate the sympathetic nervous system, affect the progression and onset of Huntington’s disease. Using a large global dataset, the study evaluated the influence of β-blockers on delaying motor symptoms and slowing the progression of symptoms in individuals at various stages of Huntington’s disease.
• In October 2024, Researchers from the University of Oxford have identified a key biochemical mechanism relevant to the development of Huntington’s disease. This discovery opens up the possibility of studying the disease before its clinical onset and eventually stopping its progression.
• In October 2024, The Cambridge, U.K.-based biotechnology company announced that it had raised £35m ($43m), led by venture capital firm Forbion. The proceeds will advance preclinical and clinical research of LoQus23’s foremost asset, its small molecule MutSβ inhibitor to advance Huntington’s disease therapy.
• In September 2024, Researchers with McMaster University have discovered that the protein mutated in patients with Huntington disease doesn't repair DNA as intended, impacting the ability of brain cells to heal themselves.

Analyst View:      

The industry for Huntington’s disease treatment market is placed for substantial growth due to high burden of HD in western countries, strong product pipeline of disease-modifying therapies, increasing population, and rise in demand for advanced drug types for controlling the symptoms. New innovations and development, advance technologies, and many collaborations and partnerships helps to boost the growth of the market in upcoming years.

More Related Reports

Liver Disease Diagnostics Market
Complex Disease Treatment Market
Rare disease Market
Alopecia Treatment Market
Crohn’s Disease Treatment Market